NCT01402271View on ClinicalTrials.gov

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 15, 2019

Study Completion Date

July 13, 2020

Conditions
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer
Interventions
DRUG

carboplatin

DRUG

paclitaxel

DRUG

pazopanib hydrochloride

OTHER

laboratory biomarker analysis

OTHER

pharmacological study

Trial Locations (9)

Unknown

Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet, Brussels

U.Z. Gasthuisberg, Leuven

C.H.U. Sart-Tilman, Liège

Centre Hospitalier Regional De La Citadelle, Liège

ZNA Jan Palfijn, Merksem

Radboud University Medical Center Nijmegen, Nijmegen

Erasmus MC, Rotterdam

Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Badalona

Hospital Clínico Universitario San Carlos, Madrid

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT01402271 - Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer | Biotech Hunter | Biotech Hunter